Effect of perioperative intravenous magnesium sulfate on postoperative pain after iliac venous stenting.

Autor: Celenlioglu AE; Department of Pain Medicine, University of Health Sciences Gulhane Training and Research Hospital, Ankara, Turkey. Electronic address: a.celenlioglu@gmail.com., Sir E; Department of Pain Medicine, University of Health Sciences Gulhane Training and Research Hospital, Ankara, Turkey., Ors-Yildirim N; Department of Anesthesia and Reanimation, University of Health Sciences Gulhane Training and Research Hospital, Ankara, Turkey., Yildirim AK; Department of Cardiovascular Surgery, Faculty of Medicine, Gazi University, Ankara, Turkey., Ince ME; Department of Anesthesia and Reanimation, University of Health Sciences Gulhane Training and Research Hospital, Ankara, Turkey., Doganci S; Department of Cardiovascular Surgery, University of Health Sciences Gulhane Training and Research Hospital, Ankara, Turkey.
Jazyk: angličtina
Zdroj: Journal of vascular surgery. Venous and lymphatic disorders [J Vasc Surg Venous Lymphat Disord] 2023 May; Vol. 11 (3), pp. 517-524. Date of Electronic Publication: 2022 Oct 18.
DOI: 10.1016/j.jvsv.2022.09.008
Abstrakt: Background: The aim of the present study was to evaluate the effect of perioperative intravenous (IV) magnesium sulfate (MS) on low back pain (LBP) severity after iliac venous stent implantation.
Methods: The present study was a single-center retrospective study. A total of 97 patients who had undergone iliac venous stenting for post-thrombotic syndrome between January 1, 2019 and January 11, 2021 were considered for inclusion in the present study. The patients were divided into two groups: those who had received perioperative MS infusions (group M) and those who had not (control group; group C). Group M was given an IV bolus of 20 mg/kg before anesthesia induction and an IV MS infusion of 20 mg/kg/h during the procedure. Postoperative LBP severity was evaluated using the numerical rating scale at 1, 6, 12, and 24 hours after the procedure. The total tramadol consumption within 24 hours was measured with the help of a patient-controlled analgesia device. Moreover, additional analgesic needs and complaints of nausea and vomiting were evaluated.
Results: A total of 97 patients were considered for inclusion in the present study. Of the 97 patients, 29 were excluded because of a lack of follow-up data, leaving 68 patients for the final analysis (group M, n = 36; group C, n = 32). The demographic data, body mass index, sedation time, procedure time, and stented side data were similar between the two groups (P > .05). The rates of atropine and ephedrine use during the procedure were similar between the two groups (P > .05). The numerical rating scale scores were significantly lower for group M at all follow-up periods (P < .001). The total tramadol consumption at 24 hours postoperatively was 191.94 ± 68.194 mg for group M and 378.75 ± 31.367 mg for group C (P < .001). Additional analgesics were used by 8 patients (22.2%) in group M and 17 patients (53.1%) in group C. Additional analgesic needs were significantly lower for group M (P = .008). Nausea and vomiting were observed in six (19.4%) and four (11.1%) patients in group M and eight (32%) and five (15.6%) patients in group C, respectively (P > .05).
Conclusions: For patients undergoing iliac venous stenting, perioperative MS infusion was an effective and safe treatment option that reduced LBP severity, opioid consumption, and the need for additional analgesics in the acute postoperative period.
(Copyright © 2022 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: